Printer Friendly

Isoprenaline: a potential contributor in sick sinus syndrome--insights from a mathematical model of the rabbit sinoatrial node.

1. Introduction

Sick sinus syndrome (SSS) comprises a variety of conditions involving sinus node dysfunction (SND) which occurs as a result of anatomical damage to the sinoatrial node (SAN) of the heart. Abnormalities encompassed in this syndrome include sinus bradycardia, sinus arrest or exit block, combinations of sinoatrial and atrioventricular nodal conduction disturbances, and atrial tachyarrhythmias [1]. Patients may experience syncope, presyncope, palpitations, or dizziness who have to be fitted with an electronic pacemaker [1, 2]. While the syndrome can occur in elderly and pediatric patients, it can also occur in healthy people without any evident structural heart disease but with genetic defects. Recent studies have shown that familial SSS is linked to loss-of-function mutations of the SCN5A gene [3], which result in decreased inward [Na.sup.+] current [4, 5].

Currently, no medications are routinely used to treat symptomatic SND. However, acute treatment with the anticholinergic agent atropine and the adrenergic agonist isoprenaline (Iso) may be warranted. Studies have shown that [beta]-adrenergic stimulation could increase the heart rate through accelerating the spontaneous activity of the pacemaker of the heart [6]. It is also believed that this occurs through [beta]-adrenoceptor mediated modulation of ionic currents that contribute to pacemaker activity [7]. Iso is a sympathomimetic [beta]-adrenergic agonist medication and known to accelerate the sinus node and enhance AV nodal conduction [8]. Experiments have shown that Iso increases the L-type calcium current [9-11] and the delayed rectifier potassium current [10, 11] and shifts voltage-dependent [i.sub.f] activation curve to more positive potentials [12-15]. Furthermore, a number of clinical studies have shown that Iso exerts positive inotropic and chronotropic effects on the heart.

Whereas, to our knowledge, many researchers have investigated the effect of Iso mainly at the cellular level, its effect on the abnormal activity at the tissue level has been rarely studied before, particularly for the abnormal activity associated with sick sinus syndrome. Thus, an intriguing problem is whether patients with SSS could recover with the help of Iso and do not need cardiac pacing. In this study, we modified models of SAN to investigate theoretically the effect of Iso on the SSS and discussed the inherent mechanism between them.

2. Methods

2.1. Model Description. In order to address the above issues, mathematical model of the rabbit central and peripheral SAN cells proposed by Kurata et al. [16] was used in this paper. The action potentials generated by using the models of a central cell and a peripheral cell were shown in Figure 1(c). Besides, a 2D anatomic model of the intact SAN-atrium tissue developed by Butters et al. [17] was also used to study the effects of Iso on SAN pacemaking and driving. This 2D intact SAN-atrium tissue model was based on histologically reconstructed geometry of a single slice of the rabbit right atrium, which was cut through the atrial muscle of the crista terminalis (CT) and the intercaval region with central and peripheral SAN areas. And an experimentally observed [18, 19] nonconductive region (block zone) next to the SAN toward the atrial septum was also incorporated in this model (see Figure 1(a)). Figure 1(b) shows the initiation and conduction of pacemaker activity computed from the 2D model. Snapshots of membrane potentials across the 2D lattice were shown at 50 ms (Figure 1(b)(1)), 70 ms (Figure 1(b)(ii)), and 90 ms (Figure 1(b)(iii)) after the initial conduction. The pacemaking action was first initiated in the center (Figure 1(b)(i)) and then propagated toward the surrounding tissues (Figure 1(b)(iii)).

The mechanism underlying the genesis of SND (clinically known as SSS) is believed to be associated with changes in the intrinsic properties of the SAN with age [20]. Intercellular electrical coupling strength (D) is considered to reflect the changes in the intrinsic properties of the SAN. To incorporate the effects of SCN5A mutation and acetylcholine (Ach) into the models, (i) parameters of the [Na.sup.+] current were changed according to the study of Butters et al. [17] and (ii) an Ach-activated [K.sup.+] current ([i.sub.K,Ach]), the inhibited L-type [Ca.sup.2+] current ([i.sub.Ca,L]), and the shift in hyperpolarization-activated current ([i.sub.f]) activation curve were introduced.

The model equations used for the cells, 2D tissue, modified [Na.sup.+] channel current, and the channel currents relative to Ach are presented in Table 1. A detailed description of parameters of these models are listed in Table 3 and can be found in [16,19-21].

2.2. Effects of Iso on Ionic Currents. In order to simulate the chronotropic effect of Iso on the pacemaker activity, Zhang et al. have incorporated a set of equations of the known actions of Iso on related ion channels into two established action potential models of rabbit SAN recently [22]. According to the study of Zhang et al., we modified the models mentioned above as follows.

(1) Based on the voltage clamp experimental data on the kinetics of ionic channels and regional differences in the ionic current densities, we incorporated equations for concentration-dependent actions of Iso on the macroscopic conductance of [i.sub.Ca,L], [i.sub.K,r], [i.sub.st], and [i.sub.K,s] and to describe changes in the kinetics of [i.sub.j] and [i.sub.K,r] by the same amount as observed experimentally [23-25].

(2) Because Iso was also found to increase the amplitude and minimal diastolic level of [[Ca.sup.2+]] in mammalian [26, 27] pacemaker cells and to alter SR [Ca.sup.2+] uptake and release by stimulation of calmodulin kinase II [26, 28], in our simulations, we adopted the approach of Kharche et al. [29] to modify the [Ca.sup.2+] handling equations to increase the amplitude and minimal diastolic level of [[Ca.sup.2+]];, as observed in experimental studies [30, 31] by increasing the maximal SR [Ca.sup.2+] release (by 20%) and reducing the SR [Ca.sup.2+] release (by 20%) fluxes.

A general remodeling of these ionic channels is given in Table 2. Using the models, the simulated effects of Iso are shown in Figure 2, in which the percentage of decrease of pacemaking cycle length (CL) is plotted against Iso concentration. The simulated data (solid line) from the central (Figure 2(a)) and the peripheral (Figure 2(b)) cell models were compared with the experimental data obtained from rabbit isolated SAN cells by Zaza et al. [23] (open circle) and Lei et al. [24, 25] (open diamond).

3. Results and Discussion

3.1. Iso Effects on SAN Cells. We discussed the effects of Iso on the dynamics of action potential in cells from the modified model. The simulated results of the action potentials under control conditions (i.e., in the absence of Iso) and in the presence of Iso (i.e., [Iso] = 0.1 [micro]M/L) are depicted in Figure 3. One can find that, with both the central and peripheral cell models, Iso shortened the action potential duration, increased the amplitude of action potentials, and caused an increase in the rate of spontaneous action potentials (Figures 3(a)(i) and 3(b)(i), dashed line). These results are consistent with experimental observations on rabbit SAN cells [23, 24].

And then, we introduced the effect of Ach into the modified models. Application of Ach slowed down pacemaking rates in both central and peripheral SAN cells, with larger effect on the central cells [32]. Simulating effects of 0.01 [micro]M/L Ach resulted in the CL increasing from 406 ms to 660 ms for the central SAN cell (Figure 3(a)(ii), solid line) and from 280 ms to 460 ms for the peripheral ones (Figure 3(b)(ii), solid line). When Iso was added (i.e, [Iso] = 0.1 [micro]M/L), the negative chronotropic effect of Ach was diminished for both types of cell models (Figures 3(a) (ii) and 3(b) (ii), dashed line).

It has been shown that the mutations slowed down pacemaking rate in peripheral, but not in central, SAN cells that control the heart rhythm [17]. Thus, we simulated the effect of Iso on pacemaking action potentials with the DelF1617 mutant channel for the peripheral SAN cells, and the results are shown in Figures 3(c)(i) and 3(c)(ii). One notices that, when only the effects of the DelF1617 mutation were introduced into the peripheral cells, the CL increased from 280 ms to 344 ms (Figure 3(c)(i), solid line). When Iso was added and its concentration was adjusted to be 0.1 [micro]M/L, the CL decreased by 14.2% (Figure 3(c)(i), dashed line). Furthermore, the negative chronotropic effect of Ach (concentration is set to be 0.01 [micro]M/L) was amplified by the mutation; that is, the cell with the wild type channel exhibited pacemaking activity (Figure 3(b)(ii), solid line), but the cell with the mutant channel became quiescent (Figure 3(c)(ii), solid line), and in this case, addition of Iso (i.e., [Iso] = 0.1 [micro]M/L) could recover the pacemaking activity of the cell with the mutant channel (Figure 3(c)(ii), dashed line). The above adjustive behavior of Iso is similar to the clinical behavior observed in patients with a longer CL [33].

3.2. Iso Effects on Two-Dimensional Tissues. We investigated further the functional influences of Iso on action potential conduction across the intact SAN-atrium under control and other conditions associated with the symptoms of SSS (i.e., DelF1617 mutation; [Ach] = 0.03 [micro]M/L; D = 0.1 [mm.sup.2]/ms). Results are shown in Figure 4, which presents the spatial and temporal profiles of action potentials recorded from representative cells across the SAN-atrium in the model (Figure 1(a)). And the conduction in the normal tissue (with the wild type channel, D = 1.0 [mm.sup.2]/ms, no Iso and no Ach) is presented in Figure 1(d).

Figure 3(a) shows the action potential profile with the DelF1617 mutation. The CL was increased by 25.8% compared with the normal tissue, and the ability of the SAN to drive atrium was not impaired. However, with Ach (i.e., [Ach] = 0.03 [micro]M/L), the mutation significantly increased the CL (Figure 4(c)) and produced a conduction block in the direction toward the atrial septum; the action potential conduction in the direction toward the CT was sustained. As we know, electrotonic interaction between the SAN and the surrounding tissues played an important role in determining the SAN pacing and driving. When the coupling strength D was fixed to be small (i.e., D = 0.1 [mm.sup.2]/ms), the SAN was able to generate spontaneous activity but failed to drive the surrounding atrium; conduction exit block occurred in both directions (Figure 4(d)).

When Iso addition was simulated at tissue level, three noteworthy results can be addressed. First, pacemaking rate with the DelF1617 mutation was significantly increased. The measured CL was decreased from 472.5 ms (Figure 4(a)) to 414.2 ms (Figure 4(b)) in the presence of 0.5 [micro]M/L Iso. Second, the spatial cessation of pacemaker activity in the direction toward the atrial septum cannot be recovered by addition of Iso (Figure 4(c)). Third, a conduction block in the direction toward the CT can be avoided. Through the application of 0.5 [micro]M/L Iso, the action potential was initiated in the center and propagated toward the CT, but not continually (Figure 4(e)); however, with the Iso concentration increasing to 2.0 [micro]M/L, the spatial cessation of pacemaker activity can be recovered completely (Figure 4(f)).

To characterize the effects of Iso, a series of simulations were performed with [Iso] changing systematically from 0.0001 [micro]M/L to 10 [micro]M/L. The results are represented in Figure 5(a), in which the computed CL was plotted against [Iso] under control conditions (solid circles), DelF1617 mutation (solid triangles), DelF1617 mutation together with [Ach] = 0.03 [micro]M/L (solid inverted triangles), and D = 0.1 [mm.sup.2]/ms (open circles). Under both control and DelF1617 mutation conditions, the SAN could pace and drive the atrium successfully. However, in the presence of 0.03 [micro]M/L Ach, the measured CL decreased with [Iso] in a similar way as under both control and DelF1617 mutation conditions; though the SAN paces, it does not drive the atrial septum (Figure 5(a), solid inverted triangles, dashed line).

When coupling strength was considered, another important phenomenon was that, in the range of 10-4 [micro]M/L < [Iso] < 10-2 [micro]M/L, the SAN failed to drive the surrounding tissues in both sides (Figure 5(a), open circles without line). When [Iso] is over 10-1 [micro]M/L, the SAN could drive the atrium continually (Figure 5(a), open circles, dashed line); however, conduction block in the atrial septum could not be avoided. Such transition happened because Iso has shown its positive effects on the pacemaker activity in the SAN. With [Iso] [greater than or equal to] 10 [micro]M/L, the pacemaker activity of the SAN was abolished completely, which suggested that high concentrations of Iso are considered toxic. These results are consistent with clinical observations by Vallin and Edhag [33] who injected Iso in 30 patients with symptoms of sinus node disease and 18 control subjects (Figure 5(b)).

The above simulations suggested that Iso plays an important role in determining the initiation and conduction of the pacemaker activity in the SAN, especially under the conditions of mutation, high [Ach], and weak coupling strength.

3.3. Role of [i.sub.Na] and [i.sub.Ca,T]. Due to the functional role of several major ionic currents, it is necessary to study the corresponding deterministic kinetics of these channel currents. Figure 6 presents the time series of the ionic currents, in which some useful clues can be found to infer the mechanism responsible for the positive effect of Iso on the pacemaker activity.

Figures 6(a)(i), (6(b)(i)), 6(a)(ii), and (6(b)(ii)) show the time series of [i.sub.Na] ([i.sub.Ca,T]) under normal condition and with the DelF1617 mutation. Compared with Figures 6(a)(i) and (6(b)(i)), [i.sub.Na]([i.sub.Ca,T]) was reduced or even zero in Figures 6(a)(ii) and (6(b)(ii)). Besides, other major underlying currents (such as [i.sub.Ca,L] and [i.sub.K,r]) were not greatly affected (data are not shown). Thus, we can conclude that the slowing of the pacemaking was primarily attributable to the mutation-induced decrease in [i.sub.Na] and [i.sub.Ca,T] (Figures 6(a)(ii) and 6(b)(ii)).

However, in this case, through the application of Iso (i.e., [Iso] = 0.1 [micro]M/L), iNa was significantly increased as well as [i.sub.Ca,T] (Figures 6(a)(iii) and 6(b)(iii)), and both of the currents can be even increased to a normal level. This means that proper concentration of Iso can increase [i.sub.Na] and [i.sub.Ca,T] which were reduced by the mutation. As a result of changes in the two currents, such abnormal pacemaking behavior could be eliminated.

4. Conclusions

In this study, by using a 2D anatomical model of the intact SAN-atrium, we have investigated the effects of Iso and the DelF1617 mutation on initiation and conduction of the pacemaker activity. The main findings of this study are as follows. (1) Iso could accelerate the pacemaking rate and affect the shape of action potentials in both the central and peripheral SAN cells, which are consistent with experimental observations [23, 24]. (2) The DelF1617 mutation slowed down pacemaking rate. Simulated addition of Ach amplified the bradycardic effect of the mutation and compromised the ability of the SAN to pace and drive the atrial septum. (3) When combined effects of Ach and the changes in the intrinsic properties of the SAN with the mutation were considered, conduction block can occur in both directions toward the atrium and CT, leading to a higher probability of SAN exit block and sinus arrest than with the mutation or Ach alone. This finding agrees with that of Smits et al. [34] and may provide further insight into the mechanism underlying high risk of cardiac arrest in SSS patients at night, when Ach concentration is high [35,36]. (4) Abnormal pacemaking or even cessation state can be eliminated by proper concentration of Iso. Functional effects of Iso on the other mutations were similar (i.e., T220I, P1298L, and E161K). What is more, Iso would be also useful for the treatment of bradycardia and improve atrial mechanical function [37]. It can be seen that these results are in good accordance with the clinical findings reported by Rokseth and Hatle [27], who provided the results of a 4-year prospective study regarding the occurrence, clinical pattern, and treatment of sinus arrest in patients with acute myocardial infarction. Taken together, we conclude that Iso could improve the pacemaking ability of the SAN cells as one of the fundamental medicines for SSS.

http://dx.doi.org/ 10.1155/2014/540496

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors gratefully acknowledge support from the China National Funds for Distinguished Young Scientists under Grants 11125419 and 10925525 and Fujian Province Funds for Leading Scientist in Universities.

References

[1] V. Adan and L. A. Crown, "Diagnosis and treatment of sick sinus syndrome," American Family Physician, vol. 67, no. 8, pp. 1725-1738, 2003.

[2] P. Alboni, L. Gianfranchi, and M. Brignole, "Treatment of persistent sinus bradycardia with intermittent symptoms: are guidelines clear?" Europace, vol. 11, no. 5, pp. 562-564, 2009.

[3] T. Zhang, S. L. Yong, X.-L. Tian, and Q. K. Wang, "Cardiac-specific overexpression of SCN5A gene leads to shorter P wave duration and PR interval in transgenic mice," Biochemical and Biophysical Research Communications, vol. 355, no. 2, pp. 444-450, 2007.

[4] J. Gui, T. Wang, R. P. O. Jones, D. Trump, T. Zimmer, and M. Lei, "Multiple loss-of-function mechanisms contribute to SCN5A-related familial sick sinus syndrome," PLoS ONE, vol. 5, no. 6, Article ID e10985, 2010.

[5] J. Zhang, X. Li, L. Liang, S. Huang, and H. Zhang, "Effects of external stimuli on the pacemaker function of the sinoatrial node in sodium channel gene mutations models," Science China Life Sciences, vol. 56, pp. 818-822, 2013.

[6] D. V. Abramochkin, V. S. Kuzmin, G. S. Sukhova, and L. V. Rosenshtraukh, "Modulation of rabbit sinoatrial node activation sequence by acetylcholine and isoproterenol investigated with optical mapping technique," Acta Physiologica, vol. 196, no. 4, pp. 385-394, 2009.

[7] F. U. Muller, P. Boknik, A. Horst et al., "In vivo isoproterenol treatment leads to downregulation of the mRNA encoding the cAMP response element binding protein in the rat heart," Biochemical and Biophysical Research Communications, vol. 215, no. 3, pp. 1043-1049, 1995.

[8] G. Vargas, M. Akhtar, and A. N. Damato, "Electrophysiologic effects of isoproterenol on cardiac conduction system in man," American Heart Journal, vol. 90, no. 1, pp. 25-34, 1975.

[9] A. Noma, H. Kotake, and H. Irisawa, "Slow inward current and its role mediating the chronotropic effect of epinephrine in the rabbit sinoatrial node," Pflugers Archiv European Journal of Physiology, vol. 388, no. 1, pp. 1-9, 1980.

[10] K. B. Walsh, T. B. Begenisich, and R. S. Kass, "[beta]-Adrenergic modulation in the heart. Independent regulation of K and Ca channels," Pflugers Archiv European Journal of Physiology, vol. 411, no. 2, pp. 232-234, 1988.

[11] Y. Ke, M. Lei, T. P. Collins et al., "Regulation of L-type calcium channel and delayed rectifier potassium channel activity by p21-activated kinase-1 in guinea pig sinoatrial node pacemaker cells," Circulation Research, vol. 100, no. 9, pp. 1317-1327, 2007

[12] H. F. Brown, D. DiFrancesco, and S. J. Noble, "How does adrenaline accelerate the heart?" Nature, vol. 280, no. 5719, pp. 235-236, 1979.

[13] A. Bucchi, M. Baruscotti, R. B. Robinson, and D. DiFrancesco, "If-dependent modulation of pacemaker rate mediated by cAMP in the presence of ryanodine in rabbit sino-atrial node cells," Journal of Molecular and Cellular Cardiology, vol. 35, no. 8, pp. 905-913, 2003.

[14] M. Baruscotti, A. Bucchi, C. Viscomi et al., "Deep bradycardia and heart block caused by inducible cardiac-specific knockout of the pacemaker channel gene Hcn4," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 4, pp. 1705-1710, 2011.

[15] Z. Liao, D. Lockhead, E. D. Larson, and C. Proenza, "Phosphorylation and modulation of hyperpolarization-activated HCN4 channels by protein kinase A in the mouse sinoatrial node," Journal of General Physiology, vol. 136, no. 3, pp. 247-258, 2010.

[16] Y. Kurata, H. Matsuda, I. Hisatome, and T. Shibamoto, "Regional difference in dynamical property of sinoatrial node pacemaking: role of [Na.sup.+] channel current," Biophysical Journal, vol. 95, no. 2, pp. 951-977, 2008.

[17] T. D. Butters, O. V. Aslanidi, S. Inada et al., "Mechanistic links between [Na.sup.+] channel (SCN5A) mutations and impaired cardiac pacemaking in sick sinus syndrome," Circulation Research, vol. 107, no. 1, pp. 126-137, 2010.

[18] H. Dobrzynski, J. Li, J. Tellez et al., "Computer three-dimensional reconstruction of the sinoatrial node," Circulation, vol. 111, no. 7, pp. 846-854, 2005.

[19] W. K. Bleeker, A. J. C. Mackaay, and M. Masson-Pevet, "Functional and morphological organization of the rabbit sinus node," Circulation Research, vol. 46, no. 1, pp. 11-22, 1980.

[20] H. Zhang, Y. Zhao, M. Lei et al., "Computational evaluation of the roles of [Na.sup.+] current, [i.sub.Na], and cell death in cardiac pacemaking and driving," American Journal of Physiology, vol. 292, no. 1, pp. H165-H174, 2007.

[21] H. Zhang, A. V. Holden, I. Kodama et al., "Mathematical models of action potentials in the periphery and center of the rabbit sinoatrial node," American Journal of Physiology, vol. 279, no. 1, pp. H397-H421, 2000.

[22] H. Zhang, T. Butters, I. Adeniran et al., "Modeling the chronotropic effect of isoprenaline on rabbit sinoatrial node," Frontiers in Physiology, vol. 3, p. 241, 2012.

[23] A. Zaza, R. B. Robinson, and D. DiFrancesco, "Basal responses of the L-type [Ca.sup.2+] and hyperpolarization-activated currents to autonomie agonists in the rabbit sino-atrial node," Journal of Physiology, vol. 491, no. 2, pp. 347-355, 1996.

[24] M. Lei, H. F. Brown, and D. A. Terrar, "Modulation of delayed rectifier potassium current, iK, by isoprenaline in rabbit isolated pacemaker cells," Experimental Physiology, vol. 85, no. 1, pp. 27-35, 2000.

[25] M. Lei, P. J. Cooper, P. Camelliti, and P. Kohl, "Role of the 293b-sensitive, slowly activating delayed rectifier potassium current, iKs, in pacemaker activity of rabbit isolated sino-atrial node cells," Cardiovascular Research, vol. 53, no. 1, pp. 68-79, 2002.

[26] V. A. Maltsev and E. G. Lakatta, "Synergism of coupled subsarcolemmal [Ca.sup.2+] clocks and sarcolemmal voltage clocks confers robust and flexible pacemaker function in a novel pacemaker cell model," American Journal of Physiology, vol. 296, no. 3, pp. H594-H615, 2009.

[27] R. Rokseth and L. Hatle, "Sinus arrest in acute myocardial infarction," British Heart Journal, vol. 33, no. 5, p. 639, 1971.

[28] T. R. Shannon, F. Wang, and D. M. Bers, "Regulation of cardiac sarcoplasmic reticulum Ca release by luminal [Ca] and altered gating assessed with a mathematical model," Biophysical Journal, vol. 89, no. 6, pp. 4096-4110, 2005.

[29] S. Kharche, J. Yu, M. Lei, and H. Zhang, "A mathematical model of action potentials of mouse sinoatrial node cells with molecular bases," American Journal of Physiology, vol. 301, no. 3, pp. H945-H963, 2011.

[30] Y.-K. Ju and D. G. Allen, "How does [beta]-adrenergic stimulation increase the heart rate? The role of intracellular [Ca.sup.2+] release in amphibian pacemaker cells," Journal of Physiology, vol. 516, no. 3, pp. 793-804, 1999.

[31] T. M. Vinogradova, K. Y. Bogdanov, and E. G. Lakatta, "[beta]-adrenergic stimulation modulates ryanodine receptor [Ca.sup.2+] release during diastolic depolarization to accelerate pacemaker activity in rabbit sinoatrial nodal cells," Circulation Research, vol. 90, no. 1, pp. 73-79, 2002.

[32] H. Zhang, A. V Holden, D. Noble, and M. R. Boyett, "Analysis of the chronotropic effect of acetylcholine on sinoatrial node cells," Journal of Cardiovascular Electrophysiology, vol. 13, no. 5, pp. 465-474, 2002.

[33] H. O. Vallin and K. O. Edhag, "Heart rate responses in patients with sinus node disease compared to controls: physiological implications and diagnostic possibilities," Clinical Cardiology, vol. 3, no. 6, pp. 391-398, 1980.

[34] J. P. P Smits, T. T. Koopmann, R. Wilders et al., "A mutation in the human cardiac sodium channel (E161K) contributes to sick sinus syndrome, conduction disease and Brugada syndrome in two families," Journal of Molecular and Cellular Cardiology, vol. 38, no. 6, pp. 969-981, 2005.

[35] R. Furlan, S. Guzzetti, W. Crivellaro et al., "Continuous 24-hour assessment of the neural regulation of systemic arterial pressure and RR variabilities in ambulant subjects," Circulation, vol. 81, no. 2, pp. 537-547, 1990.

[36] W. Baust and B. Bohnert, "The regulation of heart rate during sleep," Experimental Brain Research, vol. 7, no. 2, pp. 169-180, 1969.

[37] T. Date, A. Takahashi, Y. Iesaka et al., "Effect of low-dose isoproterenol infusion on left atrial appendage function soon after cardioversion of chronic atrial tachyarrhythmias," International Journal of Cardiology, vol. 84, no. 1, pp. 59-67, 2002.

Xiang Li, (1) Ji-qian Zhang, (2,3) and Jian-wei Shuai (1)

(1) Department of Physics and Institute of Theoretical Physics and Astrophysics, Xiamen University, Xiamen 361005, China

(2) College of Physics and Electronic Information, Anhui Normal University, Wuhu 241000, China

(3) Biological Physics Group, School of Physics and Astronomy, The University of Manchester, Manchester M139PL, UK

Correspondence should be addressed to Xiang Li; lixiangxmu@gmail.com

Received 24 October 2013; Accepted 3 December 2013; Published 21 January 2014

Academic Editors: C. Carbucicchio and K. W. Lobdell

TABLE 1: Model equations of the SAN single cell, 2D tissue, and some
channel currents.

Single cell model of SAN

dV/dt = [i.sub.Na] + [i.sub.Ca,L] + [i.sub.Ca,T] + [i.sub.K,r] +
[i.sub.K,s] + [i.sub.st] + [i.sub.to] + [i.sub.sus] + [i.sub.b,Na]
+ [i.sub.b,K] + [i.sub.NaK] + [i.sub.NaCa])/[C.sub.m]

2D intact SAN-atrium tissue model

[partial derivative]V/[partial derivative]t = [nabla] * (D[nabla]V)
- [i.sub.tot]/[C.sub.m]

Changes of sodium current induced by mutation

[MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII]

[MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII]

[MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII]

[MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII]

Effects of Ach on currents

[MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII]

[i.sub.Ca,L] = (1 - [b.sub.max] [[Ach]/[K.sub.0.5,Ca] + [Ach]]) x
[g.sub.Ca,L] ([d.sub.L][f.sub.L] + [0.006/1 + [e.sup.-(V+14.1)/6.0]]
(V - [E.sub.Ca,L])

[i.sub.f] = y[[g.sub.f,Na](V - [E.sub.Na]) + [g.sub.f,K](V - [E.sub.K])]

dy/dt = [y.sub.[infinity]] - y/[[tau].sub.y]

[y.sub.[infinity]] =  [e.sup.-(V+78.91-s)/26.2]/[e.sup.-(V+78.91-s)
/26.2] + [e.sup.(V+75.131-s)/21.25]

[[tau].sub.y] = 1000.0/[e.sup.-(V+78.91-s)/26.2] +
[e.sup.(V+75.131-s)/21.25]

[MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII]

TABLE 2: Actions of Iso on currents.

Increase of L-type [Ca.sup.2+] current

[i.sub.Ca,L] = [(1 + [f.sub.Ca,max][[Iso]/[K.sub.0.5,Ca'] + [Iso]] x
[g.sub.Ca,L]] [[f.sub.L][d.sub.L] + [0.006/1 + [e.sup.-(V+14.1)/6]]]
[(V - [E.sub.Ca,L]).sup.6]

Shift of the activation curve of hyperpolarization-activated current

[MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII]

Actions on rapid delayed rectifying [K.sup.+] current

[MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII],

[MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII]

dy/dt = [y.sub.[infinity]] - y/[[tau].sub.y],

[MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII]

Increase of slow delayed rectifying [K.sup.+] current

[MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII]

Increase of sustained inward current

[i.sub.st] = [(1 + [f.sub.st,max][[Iso]/[K.sub.0.5,st] + [Iso]]) x
[g.sub.st]] [q.sub.n][q.sub.i] (V - [E.sub.st])

Actions on [Ca.sup.2+] handling

[MATHEMATICAL EXPRESSION NOT REPRODUCIBLE IN ASCII]

TABLE 3: Model parameter values.

Glossary                                         Central SAN model

[C.sub.m]                  Cell membrane               20 pF
                             capacitance
[g.sub.Na]              Maximum [i.sub.Na]         0 [micro]S/pF
                            conductance
[g.sub.K,Ach,max]      Maximum [i.sub.K,Ach]    3.53 x [10.sup.-10]
                            conductance             [micro]S/pF
[g.sub.Ca,L]           Maximum [i.sub.Ca,L]      2.9 x [10.sup.-4]
                            conductance             [micro]S/pF
[g.sub.f,Na]           Maximum [i.sub.f,Na]     0.27 x [10.sup.-4]
                            conductance             [micro]S/pF
[g.sub.f,K]             Maximum [i.sub.f,K]     0.27 x [10.sup.-4]
                            conductance             [micro]S/pF
[g.sub.K,r]             Maximum [i.sub.K,r]     3.99 x [10.sup.-5]
                            conductance             [micro]S/pF
[g.sub.K,s]             Maximum [i.sub.K,s]     2.59 x [10.sup.-5]
                            conductance             [micro]S/pF
[g.sub.st]              Maximum [i.sub.st]      0.75 x [10.sup.-5]
                            conductance             [micro]S/pF
[E.sub.Ca,L]             Apparent reversal            46.4 mV
                           potential for
                            [i.sub.Ca,L]
[E.sub.st]               Apparent reversal            37.4 mV
                           potential for
                             [i.sub.st]
[[[Na.sup.+]].sub.o]       Extracellular              140 mM
                            [Na.sup.+]
                           concentration
[[[K.sup.+]].sub.o]        Extracellular              5.4 mM
                             [K.sup.+]
                           concentration
[K.sub.0.5,K,Ach]      [Ach] that produces a       0.28 [micro]M
                           half-maximal
                           activation of
                         [g.sub.K,Ach,max]
[K.sub.0.5,Ca]         [Ach] that produces a       0.09 [micro]M
                         half-maximal block
                          of [i.sub.Ca,L]
[K.sub.0.5,Ca']        [Iso] that produces a            7nM
                           half-maximal
                            increase of
                            [i.sub.Ca,L]
[K.sub.0.5,f]           [Ach] that produces     1.26 x [10.sup.-2]
                        a half-maximal shift         [micro]M
                           of [i.sub.f]
                          activation curve
[K.sub.0.5,f']         [Iso] that produces a          13.5 nM
                         half-maximal shift
                           of [i.sub.f]
                          activation curve
[MATHEMATICAL          [Iso] that produces a           19 nM
  EXPRESSION NOT           half-maximal
  REPRODUCIBLE IN           increase of
  ASCII]                    [g.sub.K,r]
[K.sub.0.5,Kacti]      [Iso] that produces a           7.5nM
                        half-maximal shift
                          of [i.sub.K,r]
                          activation curve
[MATHEMATICAL          [Iso] that produces a           24nM
  EXPRESSION NOT           half-maximal
  REPRODUCIBLE IN           decrease of
  ASCII]                  [[tau].sub.K,r]
[K.sub.0.5,st]         [Iso] that produces a           33 nM
                           half-maximal
                            increase of
                             [i.sub.st]
[P.sub.up]               Rate constant of           0.01 mM/ms
                        [Ca.sup.2+] uptake
                         by [j.sub.up] of
                           the network SR
[n.sub.K,Ach]          [i.sub.K,Ach] affected           1.5
                         by [Ach] and Hill
                            coefficient
[n.sub.f]              [i.sub.f] affected by           0.69
                          [Ach] and Hill
                            coefficient
[n.sub.up]             SR [Ca.sup.2+] uptake             2
                        and Hill coefficient
[n.sub.f']             [i.sub.f] affected by           0.392
                          [Iso] and Hill
                            coefficient
[S.sub.Na]              Percentage change of           0.38
                            [i.sub.Na]
                        conductance induced
                        by DelF1617 mutation
[MATHEMATICAL          Percentage change of            2.18
  EXPRESSION NOT             the fast-
  REPRODUCIBLE IN        inactivation time
  ASCII]                   constants of
                        [i.sub.Na] induced
                        by DelF1617 mutation
[MATHEMATICAL          Percentage change of            2.75
  EXPRESSION NOT             the slow-
  REPRODUCIBLE IN        inactivation time
  ASCII]                   constants of
                        [i.sub.Na] induced
                        by DelF1617 mutation
[S.sub.h]                 Parameter of the             0.128
                            shift in the
                         inactivation curve
                           of [i.sub.Na]
                            induced by
                         DelF1617 mutation
[b.sub.max]             Maximum fraction of            0.56
                         [i.sub.Ca,L] block
                           caused by Ach
[s.sub.max]               Maximum shift of            -7.2 mV
                             [i.sub.f]
                         activation curve
                           caused by Ach
[f.sub.ca,max]          Maximum percentage             0.54
                            increase of
                           [i.sub.Ca,L]
                           caused by Iso
[f.sub.K,max]            Maximum percentage            1.87
                            increase of
                         [i.sub.K,r] caused
                               by Iso
[f.sub.st.max]           Maximum percentage             1.0
                            increase of
                         [i.sub.st] caused
                               by Iso
[S.sub.f,max]            Maximum activation           9.62 mV
                           curve shift of
                          [i.sub.f] caused
                               by Iso
[S.sub.K,max]            Maximum activation           -15 mV
                           curve shift of
                         [i.sub.K,r] caused
                               by Iso
[MATHEMATICAL           Maximum decrease of             3.0
  EXPRESSION NOT          [[tau].sub.K,r]
  REPRODUCIBLE IN          caused by Iso
  ASCII]
[[alpha].sub.Iso]       Percentage increase             0.2
                             of the SR
                            [Ca.sup.2+]
                          release fluxes
                           caused by Iso
[[beta].sub.Iso]        Percentage decrease             0.2
                             of the SR
                         [Ca.sup.2+] uptake
                           caused by Iso

Glossary               Peripheral SAN model

[C.sub.m]                     65 pF

[g.sub.Na]              1.85 x [10.sup.-8]
                           [micro]S/pF
[g.sub.K,Ach,max]      1.218 x [10.sup.-9]
                           [micro]S/pF
[g.sub.Ca,L]            1.0 x [10.sup.-3]
                           [micro]S/pF
[g.sub.f,Na]            1.05 x [10.sup.-4]
                           [micro]S/pF
[g.sub.f,K]             1.05 x [10.sup.-4]
                           [micro]S/pF
[g.sub.K,r]             2.46 x [10.sup.-4]
                           [micro]S/pF
[g.sub.K,s]             1.6 x [10.sup.-4]
                           [micro]S/pF
[g.sub.st]                0 [micro]S/pF

[E.sub.Ca,L]                 46.4 mV

[E.sub.st]                   37.4 mV

[[[Na.sup.+]].sub.o]          140 mM

[[[K.sup.+]].sub.o]           5.4mM

[K.sub.0.5,K,Ach]         0.28 [micro]M

[K.sub.0.5,Ca]            0.09 [micro]M

[K.sub.0.5,Ca']                7 nM

[K.sub.0.5,f]           1.26 x [10.sup.-2]
                             [micro]M

[K.sub.0.5,f']               13.5 nM

[MATHEMATICAL                 19 nM
  EXPRESSION NOT
  REPRODUCIBLE IN
  ASCII]
[K.sub.0.5,Kacti]             7.5nM

[MATHEMATICAL                  24nM
  EXPRESSION NOT
  REPRODUCIBLE IN
  ASCII]
[K.sub.0.5,st]                33 nM

[P.sub.up]                  0.02mM/ms

[n.sub.K,Ach]                  1.5

[n.sub.f]                      0.69

[n.sub.up]                      2

[n.sub.f']                    0.392

[S.sub.Na]                     0.38

[MATHEMATICAL                  2.18
  EXPRESSION NOT
  REPRODUCIBLE IN
  ASCII]

[MATHEMATICAL                  2.75
  EXPRESSION NOT
  REPRODUCIBLE IN
  ASCII]

[S.sub.h]                     0.128

[b.sub.max]                    0.56

[s.sub.max]                  -7.2 mV

[f.sub.ca,max]                 0.54

[f.sub.K,max]                  1.87

[f.sub.st.max]                 1.0

[S.sub.f,max]                9.62 mV

[S.sub.K,max]                 -15 mV

[MATHEMATICAL                  3.0
  EXPRESSION NOT
  REPRODUCIBLE IN
  ASCII]
[[alpha].sub.Iso]              0.2

[[beta].sub.Iso]               0.2
COPYRIGHT 2014 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Li, Xiang; Zhang, Ji-qian; Shuai, Jian-wei
Publication:The Scientific World Journal
Article Type:Report
Date:Jan 1, 2014
Words:5781
Previous Article:A Schiff base-derived copper (II) complex is a potent inducer of apoptosis in colon cancer cells by activating the intrinsic pathway.
Next Article:Gene network biological validity based on gene-gene interaction relevance.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters